NO20071243L - Substituterte biarylpiperazinylpyridinanaloger. - Google Patents
Substituterte biarylpiperazinylpyridinanaloger.Info
- Publication number
- NO20071243L NO20071243L NO20071243A NO20071243A NO20071243L NO 20071243 L NO20071243 L NO 20071243L NO 20071243 A NO20071243 A NO 20071243A NO 20071243 A NO20071243 A NO 20071243A NO 20071243 L NO20071243 L NO 20071243L
- Authority
- NO
- Norway
- Prior art keywords
- biarylpiperazinylpyridine
- analogs
- substituted
- ligands
- compounds
- Prior art date
Links
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 244000144980 herd Species 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Substituerte biarylpiperazinylpyridinanaloger er gitt med formelen: hvor variabler er som beskrevet her. Slike forbindelser er ligander som kan anvendes til å modulere spesifikk reseptoraktivitet in vivo eller in vitro og er spesielt anvendelige ved behandling av lidelser forbundet med patologisk reseptoraktivering hos mennesker, tamme selskapsdyr og husdyrbesetning. Farmasøytiske preparater og metoder for anvendelse av slike forbindelser for å behandle slike lidelser er gitt, og det er også metoder for anvendelse av slike ligander for reseptorlokaliseringsundersøkelser.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60172104P | 2004-08-13 | 2004-08-13 | |
| US64179605P | 2005-01-05 | 2005-01-05 | |
| PCT/US2005/028969 WO2006026135A2 (en) | 2004-08-13 | 2005-08-13 | Substituted biaryl piperazinyl-pyridine analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071243L true NO20071243L (no) | 2007-04-27 |
Family
ID=36000525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071243A NO20071243L (no) | 2004-08-13 | 2007-03-07 | Substituterte biarylpiperazinylpyridinanaloger. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7662830B2 (no) |
| EP (1) | EP1786800B1 (no) |
| JP (1) | JP4955554B2 (no) |
| KR (1) | KR20070046924A (no) |
| CN (1) | CN101014587B (no) |
| AR (1) | AR050194A1 (no) |
| BR (1) | BRPI0514319A (no) |
| CA (1) | CA2577301C (no) |
| CR (1) | CR8992A (no) |
| EC (1) | ECSP077318A (no) |
| HN (1) | HN2007006799A (no) |
| IL (1) | IL181040A0 (no) |
| MA (1) | MA28857B1 (no) |
| MX (1) | MX2007001696A (no) |
| MY (1) | MY145822A (no) |
| NI (1) | NI200700040A (no) |
| NO (1) | NO20071243L (no) |
| NZ (1) | NZ553388A (no) |
| PE (1) | PE20060620A1 (no) |
| RU (1) | RU2413726C2 (no) |
| SG (1) | SG157399A1 (no) |
| TW (1) | TW200605889A (no) |
| WO (1) | WO2006026135A2 (no) |
| ZA (1) | ZA200701530B (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
| EP1644358A2 (en) * | 2003-07-16 | 2006-04-12 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| EP1812007B1 (en) | 2004-11-02 | 2011-09-07 | Northwestern University | Pyridazine compounds and methods |
| WO2006050389A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds, compositions and methods |
| AU2005317176A1 (en) * | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| WO2006078992A2 (en) * | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| WO2007127474A2 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| WO2007127375A2 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| US20080153845A1 (en) * | 2006-10-27 | 2008-06-26 | Redpoint Bio Corporation | Trpv1 antagonists and uses thereof |
| TWI362930B (en) * | 2007-04-27 | 2012-05-01 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
| US8343966B2 (en) * | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| AU2012225382B2 (en) * | 2011-03-09 | 2016-10-27 | Celgene Avilomics Research, Inc. | PI3 kinase inhibitors and uses thereof |
| ES2390326B1 (es) * | 2011-04-05 | 2013-08-14 | Universidad Miguel Hernández De Elche | Antagonistas de trpv1 y sus usos. |
| GEP20166432B (en) | 2011-09-27 | 2016-02-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| JP6129199B2 (ja) * | 2011-12-02 | 2017-05-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピペリジン誘導体、その医薬組成物及び使用 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| EA027732B1 (ru) | 2013-07-30 | 2017-08-31 | Янссен Сайенсиз Айрлэнд Юси | Замещенные аналоги пиридина-пиперазинила в качестве противовирусных соединений против rsv |
| CN115060832B (zh) * | 2022-08-18 | 2022-11-29 | 上海奥科达生物医药科技有限公司 | 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4921148B1 (no) | 1970-12-28 | 1974-05-30 | ||
| US3775326A (en) | 1972-04-17 | 1973-11-27 | Addressograph Multigraph | Pressure fixable electroscopic printing powder |
| FR2262512A1 (en) | 1974-03-01 | 1975-09-26 | Synthelabo | 2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity |
| DE2643753A1 (de) | 1976-09-29 | 1978-04-06 | Thomae Gmbh Dr K | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
| FI70411C (fi) * | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
| DE3609596A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| CA2090027A1 (en) | 1990-08-31 | 1992-03-01 | Shoichi Chokai | Pyrimidine derivatives and drugs |
| AU703263B2 (en) | 1994-08-08 | 1999-03-25 | Nippon Shinyaku Co. Ltd. | Triazine derivative and medicine |
| US5962453A (en) | 1995-08-08 | 1999-10-05 | Nippon Shinyaku Co. Ltd. | Triazine derivative and medicine |
| JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| ATE274510T1 (de) | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
| DE19836697A1 (de) | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AU768720B2 (en) | 1999-04-01 | 2004-01-08 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| EP1136483A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
| AU2001262150A1 (en) | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
| AU2001268718B2 (en) * | 2000-06-29 | 2006-01-05 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| JP2004525071A (ja) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| WO2002098864A1 (en) | 2001-06-01 | 2002-12-12 | F. Hoffmann-La Roche Ag | Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| EP2316831B1 (en) | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| EP1644358A2 (en) | 2003-07-16 | 2006-04-12 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| CN1826328A (zh) | 2003-07-22 | 2006-08-30 | 神经能质公司 | 经取代的吡啶-2-基胺类似物 |
| MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| AU2005317176A1 (en) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| WO2006078992A2 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| US8258143B2 (en) * | 2006-06-28 | 2012-09-04 | Duquesne University Of The Holy Ghost | Methods of using substituted pyrrolo[2,3-d]pyrimidines for targeting tumor cells and treating cancer |
-
2005
- 2005-06-22 MY MYPI20052848A patent/MY145822A/en unknown
- 2005-07-01 TW TW094122269A patent/TW200605889A/zh unknown
- 2005-08-02 AR ARP050103213A patent/AR050194A1/es unknown
- 2005-08-11 PE PE2005000929A patent/PE20060620A1/es not_active Application Discontinuation
- 2005-08-13 BR BRPI0514319-5A patent/BRPI0514319A/pt not_active IP Right Cessation
- 2005-08-13 KR KR1020077005831A patent/KR20070046924A/ko not_active Ceased
- 2005-08-13 CN CN2005800275501A patent/CN101014587B/zh not_active Expired - Fee Related
- 2005-08-13 JP JP2007525874A patent/JP4955554B2/ja not_active Expired - Fee Related
- 2005-08-13 NZ NZ553388A patent/NZ553388A/en unknown
- 2005-08-13 CA CA2577301A patent/CA2577301C/en not_active Expired - Fee Related
- 2005-08-13 US US11/204,202 patent/US7662830B2/en active Active
- 2005-08-13 ZA ZA200701530A patent/ZA200701530B/xx unknown
- 2005-08-13 EP EP05810146.0A patent/EP1786800B1/en not_active Expired - Lifetime
- 2005-08-13 MX MX2007001696A patent/MX2007001696A/es not_active Application Discontinuation
- 2005-08-13 SG SG200907610-0A patent/SG157399A1/en unknown
- 2005-08-13 WO PCT/US2005/028969 patent/WO2006026135A2/en not_active Ceased
- 2005-08-13 RU RU2007106042/04A patent/RU2413726C2/ru not_active IP Right Cessation
-
2007
- 2007-01-29 IL IL181040A patent/IL181040A0/en unknown
- 2007-02-09 NI NI200700040A patent/NI200700040A/es unknown
- 2007-02-23 HN HN2007006799A patent/HN2007006799A/es unknown
- 2007-03-07 NO NO20071243A patent/NO20071243L/no not_active Application Discontinuation
- 2007-03-13 CR CR8992A patent/CR8992A/es not_active Application Discontinuation
- 2007-03-13 MA MA29749A patent/MA28857B1/fr unknown
- 2007-03-13 EC EC2007007318A patent/ECSP077318A/es unknown
-
2010
- 2010-02-15 US US12/705,964 patent/US8334382B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071243L (no) | Substituterte biarylpiperazinylpyridinanaloger. | |
| NO20092444L (no) | Heteroarylamidderivater | |
| NO20043411L (no) | Substituerte quinazolin-4-ylamin analoger | |
| EA200970931A1 (ru) | Аналоги гетероариламидов | |
| NO20091182L (no) | 2-fenoksypyrimidinonanaloger | |
| WO2006078992A3 (en) | Heteroaryl substituted piperazinyl-pyridine analogues | |
| WO2007140383A3 (en) | Spirocyclic sulfonamides and related compounds | |
| MY154668A (en) | 5-membered heterocyclic amides and related compounds | |
| WO2005007648A3 (en) | Biaryl piperazinyl-pyridine analogues | |
| UY32591A (es) | Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1 | |
| EA201070618A1 (ru) | 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus | |
| WO2007101007A8 (en) | Aryl sulfonyl heterocycles | |
| WO2006072589A3 (en) | Disubstituted ureas as kinase inhibitors | |
| WO2008024433A3 (en) | Haloalkyl-substituted pyrimidinone derivatives | |
| MX2010010505A (es) | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). | |
| WO2005007652A3 (en) | Substituted quinolin-4-ylamine analogues | |
| WO2008066664A3 (en) | Cis-cyclohexyl substituted pyrimidinone derivatives | |
| WO2006076646A3 (en) | Heteroaryl substituted quinolin-4-ylamine analogues | |
| WO2008033739A3 (en) | Benzimidazole carboxamide derivatives | |
| WO2006081388A3 (en) | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues | |
| WO2005084401A3 (en) | Aryl substituted purine analogues | |
| WO2006042289A3 (en) | Substituted biaryl quinolin-4-ylamine analogues | |
| WO2005084368A3 (en) | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | |
| WO2006071538A3 (en) | Substituted biaryl analogues | |
| WO2009121036A3 (en) | Substituted aryl pyrimidinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |